Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension11Edited by Thomas J. Liesegang, MD

24-h IOP control with latanoprost, travoprost, and bimatoprost in subjects with exfoliation syndrome and ocular hypertension

“…In patients with POAG and XFG, the 24-h IOP findings are in accordance with most publications in the relevant literature in that the highest IOP values are generally found in the morning. 3,4,13,14,19,20 Konstas et al 3,14 reported that the most common time of maximal IOP for both POAG and XFG is 1000 hours. In our study subjects with XFS and OH, the evening and night time sitting IOP measurement were generally lower, and this is in accordance with most studies in the literature with POAG and XFG patients like Konstas et al's 4 study.…”

“…Previous studies clearly demonstrated that topical administration of latanoprost 0.005% once daily provided a steady reduction of the IOP during both the day and night in POAG and XFG. [7][8][9][10][11][12][13] To the best of our knowledge, no information is available regarding 24-h curve testing or the mean range of IOP with the newer medication such as travoprost or bimatoprost in patients with exfoliation syndrome (XFS) together with elevated IOP. The purpose of this study was to compare the effects of three PG analogues on the 24-h IOP curve in eyes with XFS and ocular hypertension (OH).…”

Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension

“…165,166 In other studies, mean reductions in IOP were lower with latanoprost than with timolol 0.5% during both the daytime and night-time hours (P # 0.05) 46,66 as timolol did not reduce IOP as much at night (P = 0.04). 66 Flattening of the 24-hour IOP curve, thus reduction in IOP fluctuations was documented for bimatoprost 63,143,163 and latanoprost, 168 importantly for NTG subjects in the latter. The 24-hour diurnal IOP was statistically lower with bimatoprost compared with latanoprost in a double-masked cross-over comparison (n = 42), although the difference was small and latanoprost better tolerated with regard to conjunctival hyperemia.…”

Glaucoma management: relative value and place in therapy of available drug treatments

“…Fatigue, weakness, and dizziness were more pronounced with alpha adrenergic agonists and beta adrenergic blockers, while taste disturbances were more common with topical carbonic anhydrase inhibitors [Tanna et al 2010]. Topical carbonic anhydrase inhibitors have also demonstrated nocturnal IOP-lowering efficacy [Orzalesi et al 2000]. …”

“…This article aims to provide an evidence-based review of the most current medical therapies available for the treatment of POAG. [Orzalesi et al 2000;Stewart et al 1986;Stewart et al 1996] Little or no effect [Orzalesi et al …”